ArticleBMC infectious diseases2018
Epidemiological characterization of respiratory tract infections caused by Mycoplasma pneumoniae during epidemic and post-epidemic periods in North China, from 2011 to 2016.
Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Economic burden ofFrontiers in public health · 2026Article
- Clinical characteristics analysis of pertussis and Mycoplasma pneumoniae infection in children.Frontiers in cellular and infection microbiology · 2026Article
- Article
- Epidemiological trends and serological profiles of respiratory pathogens in Guangzhou: an 11-year retrospective study from 2013 to 2023.Journal of thoracic disease · 2025Article
- Epidemiological characteristics of community-acquiredTranslational pediatrics · 2024Article
- The epidemic characteristics ofMicrobiology spectrum · 2024Article
- An exceptionally large wave ofTranslational pediatrics · 2024Article
- Emerging trends and concerns in Mycoplasma pneumoniae pneumonia among Chinese pediatric population.Pediatric research · 2024Article
- A Case Report ofFrontiers in cardiovascular medicine · 2024Article
- Epidemic characteristics ofAnnals of translational medicine · 2022Article
- Impact of COVID-19 Pandemic Control Measures on Infection of Other Respiratory Pathogens: A Real-world Data Research in Guangzhou, China.Journal of translational internal medicine · 2022Article
- Identification ofThe Journal of international medical research · 2022Article
- Mycoplasma pneumoniae among Chinese Outpatient Children with Mild Respiratory Tract Infections during the Coronavirus Disease 2019 Pandemic.Microbiology spectrum · 2022Article
- Effect of COVID-19 on childhood Mycoplasma pneumoniae infection in Chengdu, China.BMC pediatrics · 2021Article
- Epidemiological and clinical characteristics of suspected COVID-19 patients in the isolation ward in Guangzhou, China: a cohort study.Annals of translational medicine · 2021Article
- Clinical Characteristics and Empirical Research Model of Infectious Mononucleosis Complicated with Mycoplasma pneumoniae or/and Cytomegalovirus Infection.Computational and mathematical methods in medicine · 2021Review
- Epidemiology and molecular identification of mycoplasma pneumoniae associated with respiratory infections in Zhejiang province, China, 2008-2017.Journal of clinical laboratory analysis · 2020Article
- Molecular Characterization of Mycoplasma pneumoniae Isolates in the United States from 2012 to 2018.Journal of clinical microbiology · 2020Article
- Dynamic change ofTranslational pediatrics · 2020Article
- Early diagnosis and appropriate respiratory support for Mycoplasma pneumoniae pneumonia associated acute respiratory distress syndrome in young and adult patients: a case series from two centers.BMC infectious diseases · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMycoplasma pneumoniae (M. pneumoniae) is a commonly causative pathogen for respiratory tract infections (RTIs) in humans. The epidemiological features of M. pneumoniae infections during post-epidemic, including age distribution and the seasonality of the patients, are not well investigated.
methodsWe retrospectively analyzed the clinical data of 7835 consecutive RTIs patients (3852 adults and 3983 children) who visited a teaching hospital, and defined an epidemic (2011-2013) and a post-epidemic period (2014-2016). M. pneumoniae was detected by fluorescence-quantatitive PCR in respiratory samples. Informed consent was obtained by all adults and the legal representatives of patients aged < 18 years, and the study was approved by Institutional Review Board of Beijing Chao-Yang Hospital (project approval number 10-KE-49).
resultsThe median (IQR) age was 16 (53) years (range < 0-105 years). The M. pneumoniae positive rate was 14.4% (21.2%, epidemic; 6.7%, post-epidemic), with seasonal peaks from late summer to autumn during epidemic, and from fall to winter during post-epidemic period, which was highest in children aged 7-17 years. In epidemic, no statistical difference was found in the positive rates between children and adults among most months (except February, July and August), neither for the positive rates among age groups (P = 0.801). However, in post-epidemic period, significant differences were observed in the positive rates between children and adults in nearly every month (P< 0.05 or P< 0.001, except May), as well as in the positive rates among age groups (P< 0.001). Most of the older patient admissions and all of ICU admissions occurred during the epidemic.
conclusionsDifferent patterns of age distribution and seasonality of M. pneumoniae RTIs between epidemic and post-epidemic periods were reported. Our results suggest that M. pneumoniae should be considered as a possible pathogen in pneumonia patients admitted to the ICU in the setting of an epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.